Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
Launched by M.D. ANDERSON CANCER CENTER · Jun 27, 2019
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special treatment called negative pressure wound therapy (NPWT) to see if it helps heal the abdominal incision in obese women who are having breast reconstruction surgery. Typically, after this type of surgery, doctors use standard bandages to cover the surgical site, but this study is exploring whether using NPWT can lead to better healing. The trial is currently recruiting participants who are female, between the ages of 65 and 74, and have a body mass index (BMI) of 30 or higher.
To be eligible for this trial, women must be undergoing a specific type of breast reconstruction that involves taking tissue from the abdomen. Participants will be asked to provide their consent and will receive either the NPWT treatment or standard care during their recovery. It's important to note that women who are pregnant, unable to consent, or have allergies to certain adhesives cannot participate. This study aims to find out if NPWT can improve healing, which could lead to better outcomes for patients undergoing this important surgery.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing a free abdominal flap, including a superficial inferior epigastric artery (SIEA), deep inferior epigastric artery perforator (DIEP), or muscle-sparing transverse rectus abdominus myocutaneous (MS-TRAM) flap for breast reconstruction.
- • Patients are willing and able to give consent.
- • Body mass index (BMI) greater than or equal to 30.0.
- Exclusion Criteria:
- • Patients who are unable to provide consent.
- • Patients who are suspected or known to be pregnant.
- • Known allergy to topical adhesives.
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Edward H Chang
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials